Abstract 367: Antibodies Against Oxidized LDL, ß2 Glycoprotein I and Chlamydia pneumoniae Heat Shock Protein 70 in Acute Coronary Atherothrombosis Development
Background and aims: Atherothrombosis is the major determinant of acute cardiovascular events, such as myocardial infarction. Inflammatory processes have been linked to all phases of atherogenesis. Data suggest that atherosclerosis also constitutes an autoimmune disease. We aimed to investigate the presence of anti oxidized LDL (ox-LDL) antibodies (IgG) and anti beta 2 glycoprotein I antibodies in acute coronary atherothrombosis development.
Methods: The study included 206 participants of whom 106 were patients with acute coronary syndromes (ACS), (61.2 ± 3.21 years of age, 62% males) and 100 were age and sex matched controls with no known coronary artery disease. Patients with previous infection were excluded from the study. Blood was sampled, frozen and sent on dry ice to Immunosciences Lab. Inc (USA) for analyses. All traditional risk factors were noted. Anti ox-LDL antibodies (IgG), anti beta 2 glycoprotein I (IgG) antibodies were determined as well as anti Chlamydia pneumoniae heat shock protein (HSP) 70 (IgG) antibodies. Interleukin 6 and C- reactive protein were measured.
Results: Our data showed significant prevalence of examined antibodies in patients with ACS: 30% of patients had anti Ox-LDL antibodies (IgG) detectable, 25% had anti beta glycoprotein I antibodies compared to 8% of controls. The total of 31% patients versus 13% of controls had anti Chlamydia pneumoniae HSP 70 (IgG) antibodies detectable, RR 2.36, (1.32-4.28 95% CI for RR, p=0.003) The levels of circulating antibodies were significantly higher in patients (p<0.001). Markers of inflammation differed significantly between the groups. Our data indicated linear correlation between examined antibodies and markers of inflammation.
In conclusion, the results of our study suggest that antibodies (IgG) against Ox- LDL, beta 2 glycoprotein I and Chlamydia pneumonia HSP 70 can be detected in patients with acute coronary atherothrombosis. The clinical relevance for circulating autoantibodies in cardiovascular outcomes is still debated. We believe that further research will help to assess if those autoantibodies could improve current cardiovascular risk stratification approaches and therapeutic algorithm, both in primary and secondary prevention.
Author Disclosures: I. Burazor: None. A. Vojdani: None.
- © 2014 by American Heart Association, Inc.